Boston Partners Sells 12,151 Shares of DaVita Inc. $DVA

Boston Partners decreased its holdings in shares of DaVita Inc. (NYSE:DVA) by 13.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 79,074 shares of the company’s stock after selling 12,151 shares during the quarter. Boston Partners owned 0.11% of DaVita worth $11,264,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in DVA. National Pension Service increased its position in DaVita by 74.3% during the 1st quarter. National Pension Service now owns 197 shares of the company’s stock worth $30,000 after purchasing an additional 84 shares in the last quarter. Hantz Financial Services Inc. grew its stake in shares of DaVita by 48.1% during the second quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock worth $33,000 after buying an additional 75 shares during the last quarter. Y.D. More Investments Ltd acquired a new position in shares of DaVita during the first quarter worth $35,000. Mid American Wealth Advisory Group Inc. bought a new position in shares of DaVita in the 2nd quarter valued at $36,000. Finally, Ameritas Advisory Services LLC acquired a new stake in shares of DaVita during the 2nd quarter valued at $47,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Stock Performance

NYSE:DVA opened at $123.00 on Friday. DaVita Inc. has a fifty-two week low of $115.39 and a fifty-two week high of $179.60. The company has a 50 day simple moving average of $128.01 and a two-hundred day simple moving average of $135.55. The company has a market capitalization of $8.68 billion, a PE ratio of 12.67, a P/E/G ratio of 0.91 and a beta of 1.13.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Wednesday, October 29th. The company reported $2.51 EPS for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). DaVita had a net margin of 5.80% and a return on equity of 815.62%. The firm had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.43 billion. During the same period in the prior year, the company posted $2.59 earnings per share. The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. Research analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

Analyst Upgrades and Downgrades

DVA has been the subject of several research reports. TD Cowen dropped their target price on DaVita from $154.00 to $133.00 and set a “hold” rating for the company in a research report on Monday, November 3rd. Zacks Research downgraded DaVita from a “hold” rating to a “strong sell” rating in a research note on Thursday, October 30th. Truist Financial set a $140.00 target price on shares of DaVita in a research report on Tuesday, October 14th. Weiss Ratings restated a “hold (c+)” rating on shares of DaVita in a research report on Wednesday, October 8th. Finally, Barclays dropped their price target on shares of DaVita from $149.00 to $143.00 and set an “equal weight” rating for the company in a research note on Thursday, October 30th. Five analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus target price of $148.00.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.